- Home
- TOVX vs NCLH Comparison
TOVX vs NCLH Comparison
Compare TOVX & NCLH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- NCLH
- Stock Information
- Founded
- TOVX 2001
- NCLH 1966
- Country
- TOVX United States
- NCLH United States
- Employees
- TOVX 22
- NCLH N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- NCLH Marine Transportation
- Sector
- TOVX Health Care
- NCLH Consumer Discretionary
- Exchange
- TOVX Nasdaq
- NCLH Nasdaq
- Market Cap
- TOVX 3.2M
- NCLH 12.1B
- IPO Year
- TOVX 2006
- NCLH 2013
- Fundamental
- Price
- TOVX $1.14
- NCLH $26.92
- Analyst Decision
- TOVX Strong Buy
- NCLH Buy
- Analyst Count
- TOVX 1
- NCLH 16
- Target Price
- TOVX $6.00
- NCLH $29.27
- AVG Volume (30 Days)
- TOVX 97.3K
- NCLH 9.5M
- Earning Date
- TOVX 11-12-2024
- NCLH 10-31-2024
- Dividend Yield
- TOVX N/A
- NCLH N/A
- EPS Growth
- TOVX N/A
- NCLH N/A
- EPS
- TOVX N/A
- NCLH 1.25
- Revenue
- TOVX N/A
- NCLH $9,356,741,000.00
- Revenue This Year
- TOVX N/A
- NCLH $13.10
- Revenue Next Year
- TOVX N/A
- NCLH $8.05
- P/E Ratio
- TOVX N/A
- NCLH $21.52
- Revenue Growth
- TOVX N/A
- NCLH 15.76
- 52 Week Low
- TOVX $1.14
- NCLH $14.69
- 52 Week High
- TOVX $17.00
- NCLH $28.64
- Technical
- Relative Strength Index (RSI)
- TOVX 36.15
- NCLH 53.50
- Support Level
- TOVX $1.23
- NCLH $24.89
- Resistance Level
- TOVX $1.21
- NCLH $26.90
- Average True Range (ATR)
- TOVX 0.07
- NCLH 1.04
- MACD
- TOVX 0.01
- NCLH -0.23
- Stochastic Oscillator
- TOVX 0.00
- NCLH 56.86
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About NCLH Norwegian Cruise Line Holdings Ltd.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 66,500). It operates 32 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 41,000 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.